4//SEC Filing
Hadfield Robert 4
Accession 0001209191-20-001173
CIK 0001107421other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:07 PM ET
Size
5.5 KB
Accession
0001209191-20-001173
Insider Transaction Report
Form 4
Hadfield Robert
General Counsel and Secretary
Transactions
- Sale
Common Stock
2020-01-02$4.55/sh−16,853$76,681→ 100,719 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
ZIOPHARM ONCOLOGY INC
CIK 0001107421
Entity typeother
Related Parties
1- filerCIK 0001630687
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 5:07 PM ET
- Size
- 5.5 KB